A Phase 3 interventional study of Levonorgestrel IUS (Mirena, BAY86-5028) in Contraception, sponsored by Bayer. Completed at 49 sites in United States. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-04-28.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Menorrhagia by Bayer — none open to participants now, none under way, none of them phase 3. Menorrhagia · Bayer.
Among the 19 studies in Menorrhagia by Bayer, this one is the only one that started in 2016, is one of 6 in phase 3, and was the 14th registered.
206 studies on the registry are indexed under Menorrhagia; 35 are open to participants now.
Browse Menorrhagia studies →None of the 19 studies in Menorrhagia by Bayer is open now. The open studies under Menorrhagia, anywhere →
Of the 23 Menorrhagia studies recruiting now, 4 (17%) set no upper age limit and 19 (83%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 364 is above the median of 95 across 149 interventional studies indexed under Menorrhagia.
Median enrollment 153 across the 9 interventional studies, 886 across the 10 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Menorrhagia by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mirena during extended use (Years 6 to 8).
Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use
The Pearl Index (PI) is defined as the number of pregnancies per 100 women years. The 3-year PI (Years 6 to 8) was obtained by dividing the number of pregnancies the occurred during that time (starting at Day 1 Year 6 and up to Day 365 of Year 8) by the time (in 100 women years) that the women were at risk of getting pregnant during that time.
Time frame: Years 6 to 8 of Mirena use
Menstrual Blood Loss (MBL) During a 30-day Period Starting at the Baseline Visit and at the End of Years 6, 7 and 8
Menstrual blood loss (MBL) during a 30-day period starting at the baseline visit and at the end of Year 6, Year 7, and Year 8, measured by the alkaline hematin method. The assessment of this variable was restricted to women who had Mirena inserted for heavy menstrual bleeding (HMB).
Time frame: Baseline and end of Years 6, 7 and 8 of Mirena use
Number of Participants With Menstrual Blood Loss (MBL) (>= 80 ml Per 30 Days) at End of Year 6, 7 and 8 of Mirena Use
Categorized menstrual blood loss (MBL) (≥ 80 mL per 30 days) at end of Year 6, Year 7, and Year 8. The assessment of this variable was restricted to women who had Mirena inserted for HMB.
Time frame: At end of Year 6, 7 and 8 of Mirena use
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Adverse event (AE) was defined as any untoward medical occurrence (ie any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose 1) resulted in death, 2) was life-threatening, 3) required inpatient hospitalization or prolongation of existing hospitalization, 4) resulted in persistent or significant disability/incapacity, 5) was a congenital anomaly/birth defect, or 6) was another medically important serious event as judged by the investigator. Treatment-emergent adverse event (TEAE) was defined as an AE that occurred on Day 1 Year 6 of Mirena use or later.
Time frame: Years 6 to 8 of Mirena use
Total LNG Concentrations in Plasma Estimated Based on the Final 8-year Population Pharmacokinetics (popPK) Model
A population pharmacokinetic (popPK) analysis was performed including sparse data from the study.
Time frame: At the beginning of Year 6 (baseline) and at the end of Years 6, 7, and 8 of Mirena use
Participant's Satisfaction With Mirena by Visit
Participants were asked to evaluate their satisfaction with Mirena on a 5-point scale as very satisfied, somewhat satisfied, neither satisfied or dissatisfied, dissatisfied or very dissatisfied.
Time frame: Baseline, at end of Year 6, 7 and 8 of Mirena use
| Milestone | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Started | 364 |
| Valid for fas | 362 |
| Continued into year 7 of mirena use | 305 |
| Continued into year 8 of mirena use | 243 |
| Completed | 223 |
| Not completed | 141 |
| Withdrew: Withdrawal by subject | 33 |
| Withdrew: Lost to follow-up | 26 |
| Withdrew: Adverse event | 27 |
| Withdrew: Physician decision | 2 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Wish for pregnancy | 44 |
| Withdrew: Other reason | 5 |
| Withdrew: Not valid for analysis | 2 |
The Pearl Index (PI) is defined as the number of pregnancies per 100 women years. The 3-year PI (Years 6 to 8) was obtained by dividing the number of pregnancies the occurred during that time (starting at Day 1 Year 6 and up to Day 365 of Year 8) by the time (in 100 women years) that the women were at risk of getting pregnant during that time.
| Pregnancies per 100 women years | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use | 0.28 (0.03 to 1.00) |
Menstrual blood loss (MBL) during a 30-day period starting at the baseline visit and at the end of Year 6, Year 7, and Year 8, measured by the alkaline hematin method. The assessment of this variable was restricted to women who had Mirena inserted for heavy menstrual bleeding (HMB).
| mL/30 days | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Beginning of Year 6 (baseline) | 0.000 (0.00 to 2.32) |
| End of Year 6 | 0.000 (0.00 to 0.00) |
| End of Year 7 | 0.000 (0.00 to 0.00) |
| End of Year 8 | 0.000 (0.00 to 0.00) |
Categorized menstrual blood loss (MBL) (≥ 80 mL per 30 days) at end of Year 6, Year 7, and Year 8. The assessment of this variable was restricted to women who had Mirena inserted for HMB.
| Participants | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| End of Year 6 | 0 |
| End of Year 7 | 0 |
| End of Year 8 | 0 |
Adverse event (AE) was defined as any untoward medical occurrence (ie any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose 1) resulted in death, 2) was life-threatening, 3) required inpatient hospitalization or prolongation of existing hospitalization, 4) resulted in persistent or significant disability/incapacity, 5) was a congenital anomaly/birth defect, or 6) was another medically important serious event as judged by the investigator. Treatment-emergent adverse event (TEAE) was defined as an AE that occurred on Day 1 Year 6 of Mirena use or later.
| Participants | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Any AE | 249 |
| Any SAE | 14 |
A population pharmacokinetic (popPK) analysis was performed including sparse data from the study.
| ng/L | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| At the beginning of Year 6 (baseline) | 123 ± 38.3 |
| At the end of Year 6 | 114 ± 38.7 |
| At the end of Year 7 | 106 ± 39.2 |
| At the end of Year 8 | 100 ± 39.9 |
Participants were asked to evaluate their satisfaction with Mirena on a 5-point scale as very satisfied, somewhat satisfied, neither satisfied or dissatisfied, dissatisfied or very dissatisfied.
| Participants | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Baseline (very satisfied) | 342 |
| Baseline (somewhat satisfied) | 20 |
| Baseline (neither satisfied nor dissatisfied) | 0 |
| Baseline (dissatisfied) | 0 |
| Baseline (very dissatisfied) | 0 |
| Year 6 (very satisfied) | 279 |
| Year 6 (somewhat satisfied) | 20 |
| Year 6 (neither satisfied nor dissatisfied) | 3 |
| Year 6 (dissatisfied) | 0 |
| Year 6 (very dissatisfied) | 0 |
| Year 7 (very satisfied) | 218 |
| Year 7 (somewhat satisfied) | 20 |
| Year 7 (neither satisfied nor dissatisfied) | 1 |
| Year 7 (dissatisfied) | 3 |
| Year 7 (very dissatisfied) | 1 |
| Year 8 (very satisfied) | 207 |
| Year 8 (somewhat satisfied) | 13 |
| Year 8 (neither satisfied nor dissatisfied) | 3 |
| Year 8 (dissatisfied) | 0 |
| Year 8 (very dissatisfied) | 0 |
Collected over Years 6 to 8 of Mirena use. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levonorgestrel IUS (Mirena, BAY86-5028) | 0/362 (0%) | 14/362 (3.9%) | 107/362 (29.6%) |
| Event | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Uterine perforationInjury, poisoning and procedural complications | 3/362 |
| Suicidal ideationPsychiatric disorders | 2/362 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/362 |
| VolvulusGastrointestinal disorders | 1/362 |
| Tooth abscessInfections and infestations | 1/362 |
| Urinary tract infectionInfections and infestations | 1/362 |
| ObesityMetabolism and nutrition disorders | 1/362 |
| Radial nerve palsyNervous system disorders | 1/362 |
| Vertebral artery dissectionNervous system disorders | 1/362 |
| Cerebellar strokeNervous system disorders | 1/362 |
| Event | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Weight increasedInvestigations | 33/362 |
| Bacterial vaginosisInfections and infestations | 27/362 |
| Urinary tract infectionInfections and infestations | 27/362 |
| NasopharyngitisInfections and infestations | 21/362 |
| AnxietyPsychiatric disorders | 20/362 |
FAS (full analysis set)
| Age, Continuous(years) | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Mean | 29.4 ± 3.1 |
| Sex: Female, Male(Participants) | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Female | 362 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Hispanic or Latino | 41 |
| Not Hispanic or Latino | 319 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 9 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 51 |
| White | 273 |
| More than one race | 14 |
| Unknown or Not Reported | 13 |
| Parity(Participants) | Levonorgestrel IUS (Mirena, BAY86-5028) |
|---|---|
| Nulliparous | 171 |
| Parous | 191 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in May 2021, 53 months.
Results were first posted in Apr 2022, 11 months after primary completion.
Of 17 phase 3 interventional studies under Menorrhagia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 35. This study's 53 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levonorgestrel